Cytokinetics (CYTK)
(Delayed Data from NSDQ)
$48.30 USD
-0.68 (-1.39%)
Updated May 24, 2024 04:00 PM ET
After-Market: $48.28 -0.02 (-0.04%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth C Momentum F VGM
Brokerage Reports
0 items in cart
Cytokinetics, Incorporated [CYTK]
Reports for Purchase
Showing records 61 - 80 ( 305 total )
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
2020 Results; Critical Visibility from FDA Soon for Omecamtiv; CK-274 Should Continue to Differentiate in 2021
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
Vericiguat FDA Approval Signals a Plausible Path for Omecamtiv; Target Increased to $41
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
Busy Year Ahead for Assets Across The Pipeline; Path Forward for Omecamtiv to be Defined
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
Cytokinetics Regains Freedom to Operate Worldwide With Omecamtiv in 2021
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
CK-274 Moves Forward in REDWOOD-HCM as Expected
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
Omecamtiv Continues to Delineate Promising Target Population; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
Omecamtiv Looks for Future Without Amgen; Need FDA''s Views; Target Reduced to $22
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
Significant Signal Points to Clinical Benefits in More Than 50% Pre-Specified Population; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
3Q20 Results; GALACTIC-HF Data at AHA Set to Define Omecamtiv''s Path Forward
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
GALACTIC-HF Primary Hits; Many Open Questions Though Until AHA; Target Reduced to $43
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
COSMIC-HF Adds Another Feather to Omecamtiv?s Cap; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
Speculation Fire Gets More Gasoline; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
CK-271 Enters the Clinic as Planned While Omecamtiv?s Prime Time Is Approaching
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
2Q20 Results; Cardiac Programs Set to Impress
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
Omecamtiv Prepped for Success; Let''s Get Real About Numbers; Target Increased to $
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
Strong Monetization Track Record Continues; Target Increased to $38; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
Two Words for Investors for 2H20: Cytokinetics and Omecamtiv; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
Mavacamten Meets Pivotal Endpoints in oHCM; CK-274
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
Final Agreement Around Reldesemtiv is Achieved; The Hubble Is Focused on GALACTIC
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
COVID-19 Impacts Early Stage Trials but Key 2020 Drivers Remain on Track
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J